A Target Mutation that Renders a Cancer Drug Ineffective
Mutations in the gene PTPN11, which encodes a common enzyme called SHP2,
can result in developmental disorders, such as Noonan Syndrome, and act
as oncogenic drivers in patients with certain blood cancers. Due to the
well understood role of the enzyme SHP2 in Noonan Syndrome and in tumorigenesis,
many companies are currently trying to develop drugs that inhibit the enzyme.
Researched investigated what impact mutations to SHP2 may have on the potential
efficacy of drugs targeting this enzyme.